ROLE OF M-CSF IN THE PATHOGENESIS OF ATHEROSCLEROSIS

M-CSF 在动脉粥样硬化发病机制中的作用

基本信息

项目摘要

Macrophage(MO)-colony stimulating factor (M-CSF) importantly contributes to the development of atherosclerotic lesions. We have found that the absence of M-CSF in atherosclerosis-prone apolipoprotein (apo) E or low-density lipoprotein receptor (LDLR)- deficient mice results in substantially reduced atherosclerosis despite augmented hypercholesterolemia. Our most recent studies provide compelling evidence in favor of a direct local effect of M-CSF within the vessel wall. These advances, together with the characterization of the M-CSF-mediated induction of urokinase plasminogen activator (uPA) and matrix metalloproteinases (MMPs) cascade have prompted more refined questions on the molecular mechanisms responsible for the full range of M-CSF actions in the diseased vessel wall. In this proposal, we seek to extend our research efforts to understand the role of M-CSF in the development and disruption of arterial lesions by testing following three hypotheses: 1) pleiotropic effects of M-CSF on intimal MO and SMC are modulated mainly through the activation of nuclear factors downstream to the Ras-mediated cell signaling pathways. One such factor is the transcription factor Ets-2 that promotes cell proliferation and survival, 2) increased M-CSF activity in atherosclerotic lesions contributes to the MO -mediated matrix remodeling by up regulating the expression of uPA and MT3-MMP genes. This effect of M-CSF may play a role in plaque disruption, and 3) M-CSF up regulates the MO-specific transcription of uPA and MT3-MMP genes by activating a common set of trans-acting factors (such as Ets family of transcription factors) that form ternary complexes with AP-l and bind to cis-acting DNA elements present in the 5' regulatory region of these genes. The specific aims are: 1) to investigate the effects of M-CSF on the growth of arterial lesion-associated cells in vivo using mice lacking M-CSF and/or apoE and to perform in vitro studies using cultured cells from M-CSF-deficient mice to determine the mechanism(s) underlying the M-CSF mediated proliferation and survival of MO and SMC, 2) to determine the effects of M-CSF on the expression of uPA and MT3-MMP in cultured MO and to examine the association of M-CSF regulated production of uPA and MT3-MMP to alterations in the character of atherosclerotic lesions, and 3) to identify the cis-acting elements in the uPA and MT3-MMP promoters that mediate the inductive effects of M-CSF on the expression of these genes and to examine the signaling events connecting M-CSF with the nuclear regulators of uPA and MT3-MMP. We believe our studies will provide new and important information regarding the role of M-CSF in the development and disruption of atherosclerotic and proliferative vascular lesions and this information may prove useful in design of novel therapeutic interventions for vascular diseases.
巨噬细胞(MO)集落刺激因子(M-CSF)

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Tripathi Byasmuni Rajavashisth其他文献

Tripathi Byasmuni Rajavashisth的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Tripathi Byasmuni Rajavashisth', 18)}}的其他基金

M-CSF ISOFORMS IN ATHEROSCLEROSIS
动脉粥样硬化中的 M-CSF 亚型
  • 批准号:
    2692327
  • 财政年份:
    1998
  • 资助金额:
    $ 30.6万
  • 项目类别:
M-CSF ISOFORMS IN ATHEROSCLEROSIS
动脉粥样硬化中的 M-CSF 异构体
  • 批准号:
    6030830
  • 财政年份:
    1998
  • 资助金额:
    $ 30.6万
  • 项目类别:
M-CSF ISOFORMS IN ATHEROSCLEROSIS
动脉粥样硬化中的 M-CSF 亚型
  • 批准号:
    6389692
  • 财政年份:
    1998
  • 资助金额:
    $ 30.6万
  • 项目类别:
M-CSF ISOFORMS IN ATHEROSCLEROSIS
动脉粥样硬化中的 M-CSF 异构体
  • 批准号:
    6184012
  • 财政年份:
    1998
  • 资助金额:
    $ 30.6万
  • 项目类别:
M CSF AND THE PATHOGENESIS OF ATHEROSCLEROSIS
M CSF 与动脉粥样硬化的发病机制
  • 批准号:
    2609329
  • 财政年份:
    1994
  • 资助金额:
    $ 30.6万
  • 项目类别:
M CSF AND THE PATHOGENESIS OF ATHEROSCLEROSIS
M CSF 与动脉粥样硬化的发病机制
  • 批准号:
    2229051
  • 财政年份:
    1994
  • 资助金额:
    $ 30.6万
  • 项目类别:
ROLE OF M-CSF IN THE PATHOGENESIS OF ATHEROSCLEROSIS
M-CSF 在动脉粥样硬化发病机制中的作用
  • 批准号:
    6682346
  • 财政年份:
    1994
  • 资助金额:
    $ 30.6万
  • 项目类别:
ROLE OF M-CSF IN THE PATHOGENESIS OF ATHEROSCLEROSIS
M-CSF 在动脉粥样硬化发病机制中的作用
  • 批准号:
    6625308
  • 财政年份:
    1994
  • 资助金额:
    $ 30.6万
  • 项目类别:
M CSF AND THE PATHOGENESIS OF ATHEROSCLEROSIS
M CSF 与动脉粥样硬化的发病机制
  • 批准号:
    2029081
  • 财政年份:
    1994
  • 资助金额:
    $ 30.6万
  • 项目类别:
M CSF AND THE PATHOGENESIS OF ATHEROSCLEROSIS
M CSF 与动脉粥样硬化的发病机制
  • 批准号:
    2229052
  • 财政年份:
    1994
  • 资助金额:
    $ 30.6万
  • 项目类别:

相似海外基金

Targeted ablation of cerebral atherosclerosis using supramolecular self-assembly
利用超分子自组装靶向消融脑动脉粥样硬化
  • 批准号:
    24K21101
  • 财政年份:
    2024
  • 资助金额:
    $ 30.6万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Body composition and atherosclerosis-related biomarkers in women with endometriosis
子宫内膜异位症女性的身体成分和动脉粥样硬化相关生物标志物
  • 批准号:
    23K15842
  • 财政年份:
    2023
  • 资助金额:
    $ 30.6万
  • 项目类别:
    Grant-in-Aid for Early-Career Scientists
Targeted multimodal stimuli-responsive nanogels for atherosclerosis imaging and therapy
用于动脉粥样硬化成像和治疗的靶向多模式刺激响应纳米凝胶
  • 批准号:
    2880683
  • 财政年份:
    2023
  • 资助金额:
    $ 30.6万
  • 项目类别:
    Studentship
The Epigenetic Regulator Prdm16 Controls Smooth Muscle Phenotypic Modulation and Atherosclerosis Risk
表观遗传调节因子 Prdm16 控制平滑肌表型调节和动脉粥样硬化风险
  • 批准号:
    10537602
  • 财政年份:
    2023
  • 资助金额:
    $ 30.6万
  • 项目类别:
Role of IL-6 trans signaling in atherosclerosis development and late-stage pathogenesis
IL-6反式信号传导在动脉粥样硬化发展和晚期发病机制中的作用
  • 批准号:
    10652788
  • 财政年份:
    2023
  • 资助金额:
    $ 30.6万
  • 项目类别:
Novel Mechanisms Underlying the Development of Atherosclerosis
动脉粥样硬化发展的新机制
  • 批准号:
    10589484
  • 财政年份:
    2023
  • 资助金额:
    $ 30.6万
  • 项目类别:
Alcohol Regulation of Endothelial Plasticity in Atherosclerosis
酒精对动脉粥样硬化内皮可塑性的调节
  • 批准号:
    10585070
  • 财政年份:
    2023
  • 资助金额:
    $ 30.6万
  • 项目类别:
From genotype to phenotype in a GWAS locus: the role of REST in atherosclerosis
GWAS 位点从基因型到表型:REST 在动脉粥样硬化中的作用
  • 批准号:
    10570469
  • 财政年份:
    2023
  • 资助金额:
    $ 30.6万
  • 项目类别:
2023 Atherosclerosis
2023 动脉粥样硬化
  • 批准号:
    10675221
  • 财政年份:
    2023
  • 资助金额:
    $ 30.6万
  • 项目类别:
The role of extracellular vesicle-associated MicroRNAs in HIV-associated atherosclerosis
细胞外囊泡相关 MicroRNA 在 HIV 相关动脉粥样硬化中的作用
  • 批准号:
    10619831
  • 财政年份:
    2023
  • 资助金额:
    $ 30.6万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了